ISSN: 2159-8274

Journal Home

Journal Guideline

Cancer Discovery Q1 Unclaimed

American Association for Cancer Research Inc. United States

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Cancer Discovery is a journal indexed in SJR in Oncology with an H index of 163. It has a price of 4524 €. It has an SJR impact factor of 6,795 and it has a best quartile of Q1. It has an SJR impact factor of 6,795.

Cancer Discovery focuses its scope in these topics and keywords: cells, dna, inhibitor, tumor, pancreatic, induced, hereditary, genes, fusion, ferroptosisqa, ...

Type: Journal

Type of Copyright:

Languages:

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Oncology (Q1)

Price

4524 €

Inmediate OA

NPD

Embargoed OA

2262 €

Non OA

Metrics

6,795

SJR Impact factor

163

H Index

384

Total Docs (Last Year)

1190

Total Docs (3 years)

6976

Total Refs

9083

Total Cites (3 years)

836

Citable Docs (3 years)

6,75

Cites/Doc (2 years)

18,17

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

JAMA oncology Q1
Annals of Oncology Q1
Molecular Cancer Q1
CA - A Cancer Journal for Clinicians Q1
Journal of the National Cancer Institute Q1

Compare this journals

Aims and Scope

Best articles by citations

Gain-of-function genetic alterations of G9a drive oncogenesis

Tumor-Promoting and -Suppressive Roles of Autophagy in the Same Mouse Model of BrafV600E-Driven Lung Cancer

Insights into the Mechanism of Organ-Specific Cancer Metastasis

Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells

Social Interactomes for Enabling Research Communities

Infant high grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes

Haploinsufficiency of an RB-E2F1-Condensin II Complex Leads to Aberrant Replication and Aneuploidy

Collateral Genome Instability by DNA Damage in Mitosis

SPSB1 May Have MET Its Match during Breast Cancer Recurrence

Optimizing Next-Generation AML Therapy: Activity of Mutant IDH2 Inhibitor AG-221 in Preclinical Models

Targeting Apoptosis: A New Paradigm for the Treatment of Estrogen Receptor-Positive Breast Cancer

Large-Scale Drug Screens Support Precision Medicine

SHOW MORE ARTICLES

Predicting Cancer Drug Response: Advancing the DREAM

BluepRINT for Moderate-to-Low Penetrance Cancer Susceptibility Genes Needed: Breast Cancer and Beyond

Tumor microenvironment is critical for the maintenance of cellular states found in primary glioblastomas.

Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation

Lifting Up the HAT: Synthetic Lethal Screening Reveals a Novel Vulnerability at the CBP-p300 Axis

Dual MAPK/CDK Targeting in Melanoma: New Approaches, New Challenges

Adenoid Cystic Carcinoma Can Be Driven by MYB or MYBL1 Rearrangements: New Insights into MYB and Tumor Biology

A Little pRB Can Lead to Big Problems

Escaping Out of the Brain

Insights into Epigenetic Remodeling in VHL-Deficient Clear Cell Renal Cell Carcinoma

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

YAP Is Essential for Treg-Mediated Suppression of Antitumor Immunity